Novartis Pharma GmbH, Nürnberg, Germany.
InGef-Institute for Applied Health Research Berlin GmbH, Berlin, Germany.
J Dtsch Dermatol Ges. 2022 Aug;20(8):1101-1110. doi: 10.1111/ddg.14808. Epub 2022 Aug 1.
Lichen planus (LP) is a chronic inflammatory skin disease and is a major burden for affected patients. However, data on this condition are scarce. This study aims to expand the knowledge on the epidemiology and treatment patterns of LP using German health claims data.
This retrospective observational study was based on the InGef research database. Prevalent and incident LP patients were identified in the years 2015 and 2018. Descriptive statistics were calculated for demographic characteristics, treatment patterns, and comorbidity.
The prevalence of LP was 95.9 and the incidence was 20.1 per 100,000 individuals in 2018, corresponding to 79,605 prevalent LP cases in Germany. The first LP diagnosis was generally documented by a dermatologist or a primary care physician. Three-quarters of the incident and half of the prevalent patients received topical therapy, mostly without further systemic therapy. Comorbidity in LP patients was consistent with previously known associations.
Available treatment options remain limited, underscoring the unmet need for safe and efficacious systemic treatment modalities. Lichen planus is frequently accompanied by clinically relevant systemic comorbidity. Taken together, these observations may improve our understanding of the burden of this disease and increase diagnostic awareness among clinicians.
扁平苔藓(LP)是一种慢性炎症性皮肤病,给患者带来了沉重负担。然而,关于这种疾病的数据仍然有限。本研究旨在利用德国健康索赔数据,扩大对 LP 流行病学和治疗模式的认识。
本回顾性观察性研究基于 InGef 研究数据库。在 2015 年和 2018 年确定了现患和新发 LP 患者。对人口统计学特征、治疗模式和合并症进行了描述性统计分析。
2018 年 LP 的患病率为 95.9/100,000 人,发病率为 20.1/100,000 人,相当于德国有 79,605 例现患 LP 病例。首次 LP 诊断通常由皮肤科医生或初级保健医生记录。四分之三的新发和一半的现患患者接受了局部治疗,大多数患者没有进一步的全身治疗。LP 患者的合并症与先前已知的关联一致。
现有的治疗选择仍然有限,这突显了对安全有效的全身治疗方法的需求未得到满足。扁平苔藓常伴有临床上相关的系统性合并症。综上所述,这些观察结果可能有助于我们更好地了解这种疾病的负担,并提高临床医生的诊断意识。